Skip to content

Feasibility Study of the Treatment of Acute Ischemic Stroke Using the NOVIS Transcarotid Neuroprotection System

Feasibility Study of the Treatment of Acute Ischemic Stroke Using the NOVIS Transcarotid Neuroprotection System In Transcarotid Embolectomy

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04881162
Acronym
NITE1
Enrollment
12
Registered
2021-05-11
Start date
2021-11-02
Completion date
2023-12-11
Last updated
2025-01-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Ischemic Stroke

Keywords

mechanical thrombectomy, stroke treatment, embolic protection, transcarotid

Brief summary

Study Objective is to establish the feasibility and safety of the NOVIS Transcarotid Neuroprotection System when used for the transcarotid intervention of patients that have a failed transfemoral endovascular therapy in the case of anterior circulation strokes due to large vessel embolic occlusions.

Detailed description

This is a prospective, multi-center, single arm feasibility study for the endovascular treatment of patients with acute ischemic anterior circulation strokes due to large vessel embolic occlusions using the transcarotid approach with flow reversal. Patients enrolled into the NITE 1 Study will have failed transfemoral therapy and will be followed immediately from post-op to 90 days.

Interventions

DEVICENOVIS Transcarotid Neuroprotection System (NPS)

The NOVIS Transcarotid Neuroprotection System (NPS) is intended to provide transcarotid vascular access and embolic protection

Sponsors

Silk Road Medical
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Patients with acute ischemic anterior circulation stroke due to large vessel embolic occlusion who are candidates for endovascular therapy and in whom transfemoral therapy failed.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Summary: * 1\. Patients presenting with acute ischemic stroke of the anterior circulation with large vessel occlusions who are eligible for revascularization using endovascular therapies (stentrievers and/or aspiration devices) 2\. Occlusion of the intracranial ICA, MCA M1, proximal MCA M2, single-vessel MCA M2, dominant MCA M2, or co-dominant MCA M2 segments 3\. Patient has failed transfemoral therapy (see Appendix 4 for definition), and at least 15 minutes have elapsed from groin puncture

Exclusion criteria

Summary: * 1\. Significant disease of the ipsilateral common carotid artery on routine CTA 2\. Presence of a cervical ICA loop or other high-risk anatomical features of the ICA on routine CTA, that may preclude the use of the NOVIS NPS 3\. Any active or recent hemorrhage within the past 30 days 4\. Embolectomy contraindications a. Pre-stroke mRS ≥2 b. NIHSS ≤ 5 c. ASPECTS ≤ 5 5\. IV tPA has been or is being administered 6\. Last known well \> 24 hours ago

Design outcomes

Primary

MeasureTime frameDescription
Number of Device-related Serious Adverse Events90 DaysThe primary outcome measure assesses the number of vascular complications which include which include dissection, pseudoaneurysm, hematoma, arteriovenous fistula, thrombus formation, embolization and any vascular complication that may be attributed to the device AND requires surgical repair, surgical wound revision, transfusion, etc. The endpoint is measured at 90 days post-procedure.
Number of Other Serious Adverse Events90 DaysThe primary outcome measure assesses the number of permanent cranial nerve injury, new symptomatic ipsilateral hemorrhage and dissections related to ancillary devices. The endpoint is measured at 90 days post-procedure.
Number of Subjects With Functional Independence90 DaysFunctional independence will be evaluated by assessing the modified Rankin scale (mRS). The mRS comprises six levels from 0 to 5 of increasing severe disability with an additional level 6 indicating death. A lower score indicates a better outcome and a higher score indicates a worse outcome. A mRS score reported between 0 to 2 will be considered functionally independent and 3 to 6 to not be functionally independent or dead at point of measurement. The endpoint is measured at 90 days post-procedure.

Secondary

MeasureTime frameDescription
Neurologic Assessment90 DaysThe outcome measure measures neurological worsening of patients according to the National Institutes of Health Stroke Scale (NIHSS) at 90 days post procedure. The NIHSS is a graded neurological examination that assesses consciousness, eye movements, visual fields, motor and sensory impairments, ataxia, speech, cognition and inattention. The NIHSS is a combination of 11 components each with a particular scale as follows: level of consciousness (1a: 0-3, 1b: 0-2 and 1c: 0-2), best gaze (0-2), visual fields (0-3), facial palsy (0-3), arm motor (0-4), leg motor (0-4), limb ataxia (0-2), sensory (0-2), best language (0-3), dysarthria (0-2), extinction and inattention (0-2). The components are summed, and a lower score indicates better outcomes, and higher score indicates worse outcomes. A neurological worsening similar to a non-disabling stroke is considered scored less than or equal to 4 and a neurological worsening similar to a disabling stroke with a score equal to or greater than 5.
Carotid Access TimeHospital arrival to neck incision, neck incision to carotid exposure, neck incision to carotid exposure, neck incision to carotid artery catheterization, neck incision to femoral venous sheath access which, and neck incision to initiation of reverse flow.The endpoint measures the hospital arrival to neck incision, neck incision to carotid exposure, neck incision to carotid exposure, neck incision to carotid artery catheterization which includes the securement of the sheath, neck incision to femoral venous sheath access which includes the securement of the sheath, and neck incision to initiation of reverse flow.
Revascularization Sucess RateStart to end of index procedureThe outcome measure reports the number of patients with modified thrombolysis in cerebral infarction (mTICI) score evaluated by the contract core lab measuring angiograms collected from baseline to immediately after the end of the index procedure. The mTICI grading scale is a tool for determining the response of thrombolytic therapy for ischemic stroke on a scale between 0 to 3. A lower score indicates better outcomes and higher score indicates worse outcomes The score 2 has two additional grades of severity of 2a and 2b indicating worse outcomes along the alphabetical progression of the scale.
Technical Sucess RateStart to end of index procedureThe outcome measure will count the number patients with successful introduction of endovascular tools through the NOVIS Transcarotid NPS during the procedure. Introduction of endovascular tools will be considered successful if NPS was placed, reverse flow was established, and interventional tools were successfully delivered.
Time to Final RevascularizationHospital arrival to OR, LKW to final revascularization, admission to final revascularization, OR to final revascularization, cutdown to final revascularization, arterial introduction of interventional tools to final revascularization, total reverse flow.The endpoint measures the time of hospital arrival to operating room (OR), last known well to final revascularization, admission to final revascularization, OR to final revascularization, Cutdown to final revascularization, arterial introduction of interventional tools to final revascularization, total reverse flow time including common carotid artery (CCA) clamp to CCA unclamp.
Number of Device-Related Complications90 DaysThis outcome measure assesses the number of reported complications that may be attributed to the device through the end of all patient follow up in the study.

Countries

United States

Participant flow

Participants by arm

ArmCount
NOVIS Transcarotid Neuroprotection System (NPS)
Patients that have failed transfemoral endovascular therapy in the case of anterior circulation strokes due to large vessel embolic occlusions will enrolled in the study and treated using the NOVIS Transcarotid NPS. NOVIS Transcarotid Neuroprotection System (NPS): The NOVIS Transcarotid Neuroprotection System (NPS) is intended to provide transcarotid vascular access and embolic protection
12
Total12

Baseline characteristics

CharacteristicNOVIS Transcarotid Neuroprotection System (NPS)
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
10 Participants
Age, Categorical
Between 18 and 65 years
2 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
1 Participants
Race (NIH/OMB)
Black or African American
1 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
1 Participants
Race (NIH/OMB)
White
9 Participants
Region of Enrollment
United States
12 participants
Sex: Female, Male
Female
8 Participants
Sex: Female, Male
Male
4 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
3 / 12
other
Total, other adverse events
12 / 12
serious
Total, serious adverse events
9 / 12

Outcome results

Primary

Number of Device-related Serious Adverse Events

The primary outcome measure assesses the number of vascular complications which include which include dissection, pseudoaneurysm, hematoma, arteriovenous fistula, thrombus formation, embolization and any vascular complication that may be attributed to the device AND requires surgical repair, surgical wound revision, transfusion, etc. The endpoint is measured at 90 days post-procedure.

Time frame: 90 Days

ArmMeasureValue (NUMBER)
NOVIS Transcarotid Neuroprotection System (NPS)Number of Device-related Serious Adverse Events0 device-related serious adverse events
Primary

Number of Other Serious Adverse Events

The primary outcome measure assesses the number of permanent cranial nerve injury, new symptomatic ipsilateral hemorrhage and dissections related to ancillary devices. The endpoint is measured at 90 days post-procedure.

Time frame: 90 Days

ArmMeasureValue (NUMBER)
NOVIS Transcarotid Neuroprotection System (NPS)Number of Other Serious Adverse Events0 other serious adverse events
Primary

Number of Subjects With Functional Independence

Functional independence will be evaluated by assessing the modified Rankin scale (mRS). The mRS comprises six levels from 0 to 5 of increasing severe disability with an additional level 6 indicating death. A lower score indicates a better outcome and a higher score indicates a worse outcome. A mRS score reported between 0 to 2 will be considered functionally independent and 3 to 6 to not be functionally independent or dead at point of measurement. The endpoint is measured at 90 days post-procedure.

Time frame: 90 Days

ArmMeasureCategoryValue (COUNT_OF_PARTICIPANTS)
NOVIS Transcarotid Neuroprotection System (NPS)Number of Subjects With Functional IndependencemRS of 0 to 24 Participants
NOVIS Transcarotid Neuroprotection System (NPS)Number of Subjects With Functional IndependencemRS of 3 to 68 Participants
Secondary

Carotid Access Time

The endpoint measures the hospital arrival to neck incision, neck incision to carotid exposure, neck incision to carotid exposure, neck incision to carotid artery catheterization which includes the securement of the sheath, neck incision to femoral venous sheath access which includes the securement of the sheath, and neck incision to initiation of reverse flow.

Time frame: Hospital arrival to neck incision, neck incision to carotid exposure, neck incision to carotid exposure, neck incision to carotid artery catheterization, neck incision to femoral venous sheath access which, and neck incision to initiation of reverse flow.

ArmMeasureGroupValue (MEAN)Dispersion
NOVIS Transcarotid Neuroprotection System (NPS)Carotid Access TimeHospital arrival to neck incision100.3 minutesStandard Deviation 40.6
NOVIS Transcarotid Neuroprotection System (NPS)Carotid Access TimeNeck incision to carotid exposure13.5 minutesStandard Deviation 5
NOVIS Transcarotid Neuroprotection System (NPS)Carotid Access TimeNeck incision to carotid catheterization (includes securement of sheath)20.4 minutesStandard Deviation 7.5
NOVIS Transcarotid Neuroprotection System (NPS)Carotid Access TimeNeck incision to femoral venous sheath access (includes securement of sheath)6.8 minutesStandard Deviation 11.9
NOVIS Transcarotid Neuroprotection System (NPS)Carotid Access TimeNeck incision to initiation of reverse flow35 minutesStandard Deviation 13.2
Secondary

Neurologic Assessment

The outcome measure measures neurological worsening of patients according to the National Institutes of Health Stroke Scale (NIHSS) at 90 days post procedure. The NIHSS is a graded neurological examination that assesses consciousness, eye movements, visual fields, motor and sensory impairments, ataxia, speech, cognition and inattention. The NIHSS is a combination of 11 components each with a particular scale as follows: level of consciousness (1a: 0-3, 1b: 0-2 and 1c: 0-2), best gaze (0-2), visual fields (0-3), facial palsy (0-3), arm motor (0-4), leg motor (0-4), limb ataxia (0-2), sensory (0-2), best language (0-3), dysarthria (0-2), extinction and inattention (0-2). The components are summed, and a lower score indicates better outcomes, and higher score indicates worse outcomes. A neurological worsening similar to a non-disabling stroke is considered scored less than or equal to 4 and a neurological worsening similar to a disabling stroke with a score equal to or greater than 5.

Time frame: 90 Days

ArmMeasureCategoryValue (COUNT_OF_PARTICIPANTS)
NOVIS Transcarotid Neuroprotection System (NPS)Neurologic AssessmentNon-Disabling Stroke (NIHSS ≤ 4)8 Participants
NOVIS Transcarotid Neuroprotection System (NPS)Neurologic AssessmentDisabling Stroke (NIHSS ≥ 54 Participants
Secondary

Number of Device-Related Complications

This outcome measure assesses the number of reported complications that may be attributed to the device through the end of all patient follow up in the study.

Time frame: 90 Days

ArmMeasureValue (NUMBER)
NOVIS Transcarotid Neuroprotection System (NPS)Number of Device-Related Complications1 complications
Secondary

Revascularization Sucess Rate

The outcome measure reports the number of patients with modified thrombolysis in cerebral infarction (mTICI) score evaluated by the contract core lab measuring angiograms collected from baseline to immediately after the end of the index procedure. The mTICI grading scale is a tool for determining the response of thrombolytic therapy for ischemic stroke on a scale between 0 to 3. A lower score indicates better outcomes and higher score indicates worse outcomes The score 2 has two additional grades of severity of 2a and 2b indicating worse outcomes along the alphabetical progression of the scale.

Time frame: Start to end of index procedure

ArmMeasureCategoryValue (COUNT_OF_PARTICIPANTS)
NOVIS Transcarotid Neuroprotection System (NPS)Revascularization Sucess RatemTICI score 2b10 Participants
NOVIS Transcarotid Neuroprotection System (NPS)Revascularization Sucess RatemTICI score 32 Participants
Secondary

Technical Sucess Rate

The outcome measure will count the number patients with successful introduction of endovascular tools through the NOVIS Transcarotid NPS during the procedure. Introduction of endovascular tools will be considered successful if NPS was placed, reverse flow was established, and interventional tools were successfully delivered.

Time frame: Start to end of index procedure

ArmMeasureCategoryValue (COUNT_OF_PARTICIPANTS)
NOVIS Transcarotid Neuroprotection System (NPS)Technical Sucess RateTechnical Sucess Achieved12 Participants
NOVIS Transcarotid Neuroprotection System (NPS)Technical Sucess RateTechnical Sucess Not Achieved0 Participants
Secondary

Time to Final Revascularization

The endpoint measures the time of hospital arrival to operating room (OR), last known well to final revascularization, admission to final revascularization, OR to final revascularization, Cutdown to final revascularization, arterial introduction of interventional tools to final revascularization, total reverse flow time including common carotid artery (CCA) clamp to CCA unclamp.

Time frame: Hospital arrival to OR, LKW to final revascularization, admission to final revascularization, OR to final revascularization, cutdown to final revascularization, arterial introduction of interventional tools to final revascularization, total reverse flow.

ArmMeasureGroupValue (MEAN)Dispersion
NOVIS Transcarotid Neuroprotection System (NPS)Time to Final RevascularizationHospital arrival to operating room46.7 minutesStandard Deviation 41.9
NOVIS Transcarotid Neuroprotection System (NPS)Time to Final RevascularizationLast known well to final reperfusion628.9 minutesStandard Deviation 336
NOVIS Transcarotid Neuroprotection System (NPS)Time to Final RevascularizationAdmission to final reperfusion156.7 minutesStandard Deviation 32
NOVIS Transcarotid Neuroprotection System (NPS)Time to Final RevascularizationOperating room to final reperfusion110.0 minutesStandard Deviation 43.05
NOVIS Transcarotid Neuroprotection System (NPS)Time to Final RevascularizationCutdown to final reperfusion56.3 minutesStandard Deviation 25.1
NOVIS Transcarotid Neuroprotection System (NPS)Time to Final RevascularizationArterial introduction of interventional tools to final reperfusion22.0 minutesStandard Deviation 24.2
NOVIS Transcarotid Neuroprotection System (NPS)Time to Final RevascularizationTotal reverse flow time (CCA clamp to CCA unclamp)20.3 minutesStandard Deviation 26.2

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026